Reata Pharmaceuticals Inc. (NASDAQ: RETA) is 151.01% higher on its value in year-to-date trading and has touched a low of $18.47 and a high of $106.69 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RETA stock was last observed hovering at around $79.22 in the last trading session, with the day’s gains setting it 16.14% off its average median price target of $107.00 for the next 12 months. It is also 46.73% off the consensus price target high of $179.00 offered by analysts, but current levels are -19.2% lower than the price target low of $80.00 for the same period.
Currently trading at $95.36, the stock is 3.12% and 2.97% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.47 million and changing 20.37% at the moment leaves the stock 88.01% off its SMA200. RETA registered 238.16% gain for a year compared to 6-month gain of 162.12%. The firm has a 50-day simple moving average (SMA 50) of $1.97k and a 200-day simple moving average (SMA200) of -$9.50.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The stock witnessed a -4.40% loss in the last 1 month and extending the period to 3 months gives it a 89.02%, and is 16.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.73% over the week and 5.28% over the month.
Reata Pharmaceuticals Inc. (RETA) has around 321 employees, a market worth around $3.64B and $1.50M in sales. Distance from 52-week low is 416.30% and -10.62% from its 52-week high. The company has generated returns on investments over the last 12 months (420.00%).
Reata Pharmaceuticals Inc. (RETA) Analyst Forecasts
Reata Pharmaceuticals Inc. is expected to release its quarterly report on 08/07/2023.The EPS is expected to shrink by -4.30% this year
Reata Pharmaceuticals Inc. (RETA) Top Institutional Holders
The shares outstanding are 36.95M, and float is at 30.57M with Short Float at 15.68%.
Reata Pharmaceuticals Inc. (RETA) Insider Activity
A total of 60 insider transactions have happened at Reata Pharmaceuticals Inc. (RETA) in the last six months, with sales accounting for 41 and purchases happening 19 times. The most recent transaction is an insider sale by Meyer Colin John, the company’s Chief Innovation Officer. SEC filings show that Meyer Colin John sold 625 shares of the company’s common stock on May 16 at a price of $80.94 per share for a total of $50590.0. Following the sale, the insider now owns 78373.0 shares.
Reata Pharmaceuticals Inc. disclosed in a document filed with the SEC on May 16 that Soni Manmeet Singh (COO, CFO and President) sold a total of 625 shares of the company’s common stock. The trade occurred on May 16 and was made at $80.93 per share for $50584.0. Following the transaction, the insider now directly holds 0.12 million shares of the RETA stock.
Still, SEC filings show that on May 16, WORTLEY MICHAEL D (Chief Legal Officer) disposed off 417 shares at an average price of $80.99 for $33773.0. The insider now directly holds 46,781 shares of Reata Pharmaceuticals Inc. (RETA).
Reata Pharmaceuticals Inc. (RETA): Who are the competitors?
The company’s main competitors (and peers) include Omeros Corporation (OMER) that is 113.79% higher over the past 12 months.
